Dr Reddy’s Laboratories Reports Real-World Study Results of Redditux (biosimilar, rituximab) for Diffuse Large B-Cell Lymphoma
Shots:
- Dr. Reddy’s Laboratories highlighted the real-world study in Turkey evaluating Redditux + CHOP vs Rituxan + CHOP in patients with hematological malignancies incl. DLBCL
- The results showed that the patients treated with rituximab biosimilar had similar OS over Rituxan, ORRs (86% vs 84%); CR (72.5% vs 82%); PR (13.5% vs 2%); patients had the refractory disease (14% vs 15.6%), respectively
- The 24mos. PFS rates (74% vs 85%) while 45.5% vs 63% for patients with high revised International Prognostic Index scores, CNS relapse was higher in the biosimilar group (10% vs 1.83%) with bone involvement. Patients experiencing grade 2 infusion reactions (20%) & no serious AEs resulted in cessation of rituximab therapy
Ref: Center For Biosimilars | Image: Dr Reddy
Related News:- Dr Reddy's Acquires an Exclusive License for Pregene's PRG1801 in India
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
